Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 5 mechanisms across 28 industry trials with a known mechanism of action.

See full pipeline →

RANK Ligand Inhibitor

10 trials 1 active 3 sponsors

Parathyroid Hormone Analog

9 trials 4 sponsors

Farnesyl pyrophosphate synthase

6 trials 1 sponsor

Parathyroid Hormone-Related Peptide Analog

2 trials 1 sponsor

Tumor Necrosis Factor Blocker

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

150 industry-sponsored trials across 60 sponsors

View full landscape →

Showing 17 of 17 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Amgen	Prolia®	—	RECRUITING	2027-05-24	NCT06588153
Amgen	Prolia	RANK Ligand Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-01-23	NCT06332014
Amgen	Romosozumab	—	COMPLETED	2025-10-18	NCT06079476
Dong-A ST Co., Ltd.	Risedronate Sodium 35 MG [Actonel]	—	COMPLETED	2025-07-23	NCT05630768
Amgen	—	—	COMPLETED	2017-12-18	NCT02576652
Eli Lilly	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2016-07	NCT01709110
Eli Lilly	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2015-08	NCT00887354
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2015-01-07	NCT01732770
Eli Lilly	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2014-06	NCT01753856
Hanlim Pharm. Co., Ltd.	Risedronate/Cholecalciferol combination(montly)	—	COMPLETED	2014-05-29	NCT01904110
Hanlim Pharm. Co., Ltd.	Risedronate/Cholecalciferol combination	—	COMPLETED	2013-12	NCT01675297
Organon and Co	alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)	—	COMPLETED	2013-01-10	NCT01350934
Eli Lilly	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2011-12	NCT01430104
Eli Lilly	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2010-10	NCT00927186
Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2010-07	NCT00745485
Organon and Co	alendronate sodium (+) cholecalciferol	—	COMPLETED	2009-04-10	NCT00729651
Warner Chilcott	risedronate	—	TERMINATED	2009-02	NCT00577395

Showing 65 of 65 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	QL1206	—	RECRUITING	2027-01	NCT07062978
Mabwell (Shanghai) Bioscience Co., Ltd.	9MW0311	—	RECRUITING	2026-04-30	NCT06804590
Qilu Pharmaceutical Co., Ltd.	QLG2128	—	NOT YET RECRUITING	2027-05	NCT06898060
Shanghai Biomabs Pharmaceutical Co., Ltd.	CMAB807 Injection	—	COMPLETED	2024-11-01	NCT04591275
Enzene Biosciences Ltd.	ENZ215	—	COMPLETED	2024-07-18	NCT05405725
Biocon Biologics UK Ltd	Bmab 1000	—	COMPLETED	2024-06-12	NCT05345691
Alvotech Swiss AG	AVT03	—	COMPLETED	2024-05-07	NCT05395091
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL056 (56.5μg)	—	COMPLETED	2023-12-30	NCT07028320
mAbxience Research S.L.	MB09 (denosumab biosimilar)	—	COMPLETED	2023-12-14	NCT05338086
UCB Biopharma SRL	Romosozumab	—	COMPLETED	2023-11-09	NCT05067335
Gedeon Richter Plc.	RGB-14-P	—	COMPLETED	2023-10-02	NCT05087030
Fresenius Kabi SwissBioSim GmbH	FKS518	—	COMPLETED	2023-08-07	NCT04934072
Celltrion	CT-P41	—	COMPLETED	2023-05-18	NCT04757376
Teva Pharmaceuticals USA	—	—	COMPLETED	2022-12-31	NCT04729621
Samsung Bioepis Co., Ltd.	SB16 (Proposed Denosumab Biosimilar)	—	COMPLETED	2022-06-20	NCT04664959
Novartis	GP2411	—	COMPLETED	2022-04-22	NCT03974100
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2021-12-13	NCT03164928
Radius Health, Inc.	—	—	COMPLETED	2021-10-05	NCT04064411
Mabwell (Shanghai) Bioscience Co., Ltd.	MW031	—	COMPLETED	2021-09-27	NCT05215977
Radius Health, Inc.	Abaloparatide	Parathyroid Hormone-Related Peptide Analog [EPC]	COMPLETED	2021-08-17	NCT03512262
Radius Health, Inc.	Abaloparatide	Parathyroid Hormone-Related Peptide Analog [EPC]	COMPLETED	2020-07-15	NCT03710889
Amgen	romosozumab HCP administration with PFS	—	COMPLETED	2019-04-11	NCT03432533
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2019-02-27	NCT01197300
Pfenex, Inc	Teriparatide (PF708)	—	COMPLETED	2018-05	NCT03002428
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2018-03-05	NCT00799266
Amgen	Romosozumab	—	COMPLETED	2018-02-12	NCT02791516
Amgen	Romosozumab	—	COMPLETED	2017-02-27	NCT01631214
Radius Health, Inc.	Alendronate	—	COMPLETED	2016-10-03	NCT01657162
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2016-05-12	NCT00925600
Amgen	Romosozumab	—	COMPLETED	2016-02-15	NCT02186171
Amgen	Romosozumab	—	COMPLETED	2015-12-14	NCT01575834
Takeda	NE-58095 IR	—	COMPLETED	2015-11	NCT02063854
GSK	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2015-08	NCT02014467
Amgen	Denosumab (CP2)	—	COMPLETED	2015-07	NCT02157948
Amgen	Romozosumab	—	COMPLETED	2015-05-14	NCT01796301
Asahi Kasei Therapeutics Corporation	AK156	—	COMPLETED	2015-01	NCT01522521
Radius Health, Inc.	BA058 80 mcg	—	COMPLETED	2014-10	NCT01343004
Amgen	Romosozumab 90 mg/mL	—	COMPLETED	2014-09-08	NCT02016716
Roche	ibandronate [Bonviva/Boniva]	—	COMPLETED	2014-07	NCT01290094
Merck	Odanacatib	—	COMPLETED	2013-07-22	NCT01120600
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2013-04	NCT00718861
Chiesi Farmaceutici S.p.A.	disodium clodronate 200 mg/4 ml with 1% lidocaine	—	COMPLETED	2013-03	NCT01348243
GSK	denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2013-02	NCT01495000
Organon and Co	MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet	—	COMPLETED	2012-12-05	NCT01437111
GSK	denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2012-12	NCT01457950
Alvogen Korea	Test group	—	COMPLETED	2012-09	NCT01581320
Daiichi Sankyo Co., Ltd.	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2012-06	NCT00680953
Amgen	Actonel®	—	COMPLETED	2011-12-21	NCT00919711
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2011-12	NCT00909961
Amgen	Ibandronate	—	COMPLETED	2011-11	NCT00936897
Amgen	60 mg denosumab	—	COMPLETED	2011-06-21	NCT00980174
Pfizer	bazedoxifene 20 mg/ conjugated estrogens 0.45 mg	—	COMPLETED	2011-02	NCT00808132
Tarsa Therapeutics, Inc.	Oral Calcitonin Tablets	—	COMPLETED	2011-02	NCT00959764
Hanlim Pharm. Co., Ltd.	risedronate combine	—	COMPLETED	2010-08	NCT01806792
Organon and Co	FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)	—	COMPLETED	2010-07	NCT00692913
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2010-06	NCT00890981
Astellas Pharma Inc	YM529 / ONO-5920	—	COMPLETED	2010-04	NCT00794443
Merck	Odanacatib	—	COMPLETED	2010-03-23	NCT00729183
Eli Lilly	teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2008-05	NCT00577863
Hamad Medical Corporation	Denosumab 60 MG/ML Prefilled Syringe	—	TERMINATED	2019-04-08	NCT03040765
Merck	odanacatib	—	TERMINATED	2014-11-11	NCT01803607
Evangelisches Krankenhaus Lutherhaus gGmbH	Alendronate	—	TERMINATED	2013-03	NCT01512446
Novartis	Zoledronic Acid	Farnesyl pyrophosphate synthase	TERMINATED	2012-06	NCT01166178
Xentria, Inc.	MAB-22	—	WITHDRAWN	2027-10	NCT06504966
Merck	Odanacatib	—	WITHDRAWN	2015-02	NCT01552122

Showing 25 of 25 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL056 56.5μg	—	RECRUITING	2026-07-30	NCT07579936
Angitia Biopharmaceuticals	AGA2118	—	ACTIVE NOT RECRUITING	2026-12	NCT06577935
Entera Bio Ltd.	EBP05	—	COMPLETED	2021-04-27	NCT04003467
dsm-firmenich Switzerland AG	—	—	COMPLETED	2018-09	NCT02527668
Pfizer	rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)	—	COMPLETED	2015-04-24	NCT00752557
Amgen	Romosozumab	—	COMPLETED	2014-10-09	NCT01992159
Ultragenyx Pharmaceutical Inc	BPS804 20mg/Kg	—	COMPLETED	2013-10	NCT01406548
Radius Health, Inc.	Abaloparatide Transdermal (50 mcg)	—	COMPLETED	2013-08-02	NCT01674621
Eli Lilly	LY2541546	—	COMPLETED	2012-05	NCT01144377
Unigene Laboratories Inc.	PTH analog	—	COMPLETED	2011-10	NCT01321723
Merck	Odanacatib	—	COMPLETED	2011-09-15	NCT00885170
Eli Lilly	Subcutaneous Teriparatide	—	COMPLETED	2011-09	NCT01011556
PhytoHealth Corporation	PH3	—	COMPLETED	2011-07	NCT00693667
Merck	MK-5442	—	COMPLETED	2011-06	NCT00996801
X-pert Med GmbH	—	—	COMPLETED	2011-04	NCT01415050
Amgen	Alendronate	—	COMPLETED	2011-02-21	NCT00896532
Amgen	Previous denosumab	—	COMPLETED	2010-06	NCT00887965
BioActor	—	—	COMPLETED	2010-03	NCT00789425
Warner Chilcott	150 mg	—	COMPLETED	2009-10	NCT00918749
Eli Lilly	arzoxifene	—	COMPLETED	2009-10	NCT00767299
TransPharma Medical	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2009-03	NCT00535860
Tarsa Therapeutics, Inc.	Recombinant Salmon Calcitonin (rsCT)	—	COMPLETED	2008-04	NCT00620854
Elvir SAS	—	—	COMPLETED	—	NCT00663221
Merck	MK-5442	—	TERMINATED	2010-12	NCT00960934
Nastech Pharmaceutical Company, Inc.	Teriparatide	Parathyroid Hormone Analog [EPC]	WITHDRAWN	2009-04	NCT00624481

Showing 43 of 43 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
HELP Therapeutics Co., Ltd.	Human Umbilical Cord-derived Mesenchymal stem cell	—	ACTIVE NOT RECRUITING	2026-03-06	NCT06949137
Entera Bio Ltd.	EBP05	—	COMPLETED	2026-02-08	NCT05965167
QuadMedicine	TeriQ Patch	—	COMPLETED	2024-12-30	NCT06644040
Angitia Biopharmaceuticals	AGA2118	—	COMPLETED	2024-01-13	NCT05225857
Jiangsu HengRui Medicine Co., Ltd.	SHR-1222	—	COMPLETED	2022-07-18	NCT04435158
Radius Health, Inc.	—	—	COMPLETED	2021-02-09	NCT04936984
Mabwell (Shanghai) Bioscience Co., Ltd.	MW031	—	COMPLETED	2020-12-07	NCT04798313
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL001	—	COMPLETED	2020-10-30	NCT04747392
Shanghai Biomabs Pharmaceutical Co., Ltd.	Prolia®	—	COMPLETED	2020-03-21	NCT03925051
Jiangsu HengRui Medicine Co., Ltd.	SHR-1222	—	COMPLETED	2019-10-14	NCT03870100
Radius Health, Inc.	—	—	COMPLETED	2019-05-14	NCT04366726
Addpharma Inc.	Raloxifene 60mg/Cholecalciferol 800IU	—	COMPLETED	2019-03-27	NCT03824171
Addpharma Inc.	AD-101 45mg	—	COMPLETED	2019-01-02	NCT03764462
Hyundai Pharmaceutical Co., LTD.	Bazedoxifene / Cholecalciferol	—	COMPLETED	2017-12-21	NCT03382314
Hyundai Pharmaceutical Co., LTD.	Bazedoxifene 20 mg	—	COMPLETED	2017-08-14	NCT03234244
Red de Terapia Celular	Fucosylated MSC for Osteoporosis	—	COMPLETED	2016-12	NCT02566655
Pfenex, Inc	Teriparatide	Parathyroid Hormone Analog [EPC]	COMPLETED	2016-07	NCT02656810
Zosano Pharma Corporation	ZP-PTH	—	COMPLETED	2015-11	NCT02478879
Soredab	—	—	COMPLETED	2015-05	NCT01478724
GSK	denosumab 60mg	—	COMPLETED	2015-02-17	NCT02135640
Eli Lilly	Blosozumab	—	COMPLETED	2014-07	NCT02109042
Amgen	Romosozumab	—	COMPLETED	2014-02-19	NCT01833754
Asahi Kasei Therapeutics Corporation	AK159	—	COMPLETED	2014-02	NCT01935479
Amgen	Romosozumab	—	COMPLETED	2012-11-21	NCT01588509
Asahi Kasei Therapeutics Corporation	AK159	—	COMPLETED	2012-09	NCT01551602
Yuyu Pharma, Inc.	Maxmarvil®	—	COMPLETED	2012-07	NCT01526278
Pfizer	RN564	—	COMPLETED	2012-05-24	NCT01293487
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2011-07	NCT01221727
Eli Lilly	LY333334	—	COMPLETED	2011-05	NCT01250145
Novartis	PTH134	—	COMPLETED	2011-04	NCT01224717
Merck	Odanacatib	—	COMPLETED	2010-04-26	NCT01068262
Halozyme Therapeutics	rHuPH20	—	COMPLETED	2009-09-21	NCT00807963
Astellas Pharma Inc	ONO-5920 / YM529	—	COMPLETED	2009-09	NCT00965978
Warner Chilcott	risedronate DR (Phase III clinical supply)	—	COMPLETED	2009-05	NCT00846196
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	ACE-011 or placebo	—	COMPLETED	2008-11	NCT00709540
Novartis	PTH134	—	COMPLETED	2008-08	NCT00676312
Warner Chilcott	Risedronate	—	COMPLETED	2008-02	NCT00699777
GSK	Ronacaleret	—	COMPLETED	—	NCT00651534
Merck	Odanacatib	—	TERMINATED	2016-07-14	NCT01630616
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	TERMINATED	2016-01	NCT01294397
Eli Lilly	Blosozumab	—	TERMINATED	2015-03	NCT02337387
Cephalon	CEP-37251	—	TERMINATED	2010-10	NCT01159873
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0123	—	ENROLLING BY INVITATION	2026-02-05	NCT07384104

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Osteoporosis

ER (Estrogen Receptor) (27)

Novel Drugs by Company (New molecular entities)

Amgen 2 drugs

Novartis 1 drug

BIOCON BIOLOGICS INC 1 drug

BOSAYA

DENOSUMAB-KYQQ

BLA 2025

SAMSUNG BIOEPIS CO LTD 1 drug

RADIUS 1 drug

CELLTRION INC 1 drug

SHANGHAI HENLIUS BIOTECH 1 drug

Hikma 1 drug

Pfizer 1 drug

AMNEAL PHARMS LLC 1 drug

BONCRESA

DENOSUMAB-MOBZ

BLA 2025

+1 more companies

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.